Clarivate Epidemiology's coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of CHD for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology's CHD forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of CHD?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CHD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four CHD patient populations, as follows:
Diagnosed prevalent cases: CHD.
Diagnosed prevalent cases: CHD with stable angina.
Diagnosed prevalent cases: CHD with no stable angina.
Diagnosed Prevalence of Coronary Heart Disease per 1,000 People of All Ages in 2021 and 2041
Relative Sizes of the Contributing Factors to the Trend in the Diagnosed Prevalent Cases of Coronary Heart Disease over the Next 10 Years
Analysis of the Diagnosed Prevalent Cases of Coronary Heart Disease in 2021 by Comorbidityt
Diagnosed Coronary Heart Disease With Stable Angina
Lifetime DALYs Gained
Studies Included in the Analysis of Coronary Heart Disease
Studies Excluded from the Analysis of Coronary Heart Disease
Risk/Protective Factors for Coronary Heart Disease
Ansuman Swain, B.D.S., M.P.H.,is an associate epidemiologist at Clarivate. As part of his M.P.H. curriculum, he worked as an intern at the National Health Mission in Odisha, India, where he observed the implementation of the RBSK program. Mr. Swain is a graduate in dentistry from KIIT University in Odisha and holds an M.P.H. degree from Manipal Academy of Higher Education in Karnataka, India, with a specialization in global health from Maastricht University in the Netherlands.
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.